NEW TREATMENTS FOR RETINAL DISEASE
Chairpersons:
Dr. Olaf Strauss, Charite, University Medicine Berlin, Germany
Dr. Achim Krauss, GlaxoSmithKline, USA
Confirmed speakers:
Dr. Leopold Schmetterer, Medical University of Vienna, Austria
Anti VEGF therapy – current concepts, unresolved questions and future directions
Dr. Achim Krauss, GlaxoSmithKline, USA
Topical Pazopanib Effect on VEGF-Induced Retinal Vascular Leakage and Neovascularization
Dr. Husam Younis, ISIS Pharmaceuticals, USA
Development of Antisense Oligonucleotides for Ocular Disease – Emphasis on Preclinical Ocular PK, Safety and Pharmacology and Clinical Translation
Dr. Ashwath Jayagopal, Vanderbilt Eye Institute, USA
Nanotechnology-Guided Targeted Therapy for Retinal Vascular Diseases
Dr. Olaf Strauss, Charite, University Medicine Berlin, Germany
The local renin-angiotensin-system under systemic influence: new targets for therapy
Dr. Francesca Doonan, University College Cork, Ireland
Neuroprotection of retinal photoreceptors by norgestrel, a synthetic progestin
Eventos / Esdeveniments / Events
| « Nov |
|
Jan » |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 | 31 | |||||
